Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "inflammatory"

240 News Found

Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
Biotech | February 25, 2022

Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb

It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).


Resolution Therapeutics strengthens its team with two new appointments
People | February 20, 2022

Resolution Therapeutics strengthens its team with two new appointments

Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance


Ribon Therapeutics appoints Prakash Raman as President and CEO
People | February 18, 2022

Ribon Therapeutics appoints Prakash Raman as President and CEO

Dr. Raman has succeeded Victoria Richon


WHO prequalifies first monoclonal antibody - tocilizumab – to treat Covid-19
Drug Approval | February 14, 2022

WHO prequalifies first monoclonal antibody - tocilizumab – to treat Covid-19

The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification


USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
Drug Approval | February 10, 2022

USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences

Adds five years of market exclusivity on approval


Sanofi unveils new corporate brand and logo
News | February 05, 2022

Sanofi unveils new corporate brand and logo

Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019


USFDA approves first generic of Restasis
Drug Approval | February 03, 2022

USFDA approves first generic of Restasis

Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug


CAS launches major biology expansion
Digitisation | February 01, 2022

CAS launches major biology expansion

The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists


Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
Biotech | January 22, 2022

Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study

UCB plans to submit regulatory applications in Q3 2022